IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : BONNEY

Serial No.: 10/597624 Art Unit: 3763

Filing Date: August 1, 2006 Examiner: Campbell, Victoria A.

For: Fluid Dispenser

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

Report are listed on the attached form PTO-1449 and Applicants understand that co been supplied to the U.S. Patent Office by the International Bureau. A. [] The Information Disclosure Statement submitted herewith is being filed within months of the filing date of the above application or date of entry into the national application or before the mailing date of a first Office action merits, whichever event occurs last. 37 CFR 1.97(b). OR [X] The Information Disclosure Statement submitted herewith is being filed mailing of a first office action after the filing of a Request For Continue Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)). B. [] The Information Disclosure Statement transmitted herewith is being filed after the of the filing date of the above application or the date of entry into the national staforth in § 1.491 of an international application or after the mailing date of the first Action on the merits, whichever event occurred last, but before the mailing date (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first. [] Applicant hereby certifies that each item of information contained in this Informat Disclosure Statement was cited in a communication from a foreign patent office counterpart foreign application not more than three months prior to the filing of the statement.	TIE EX	animer and officially made of record in accordance with the provisions of 37 GFK 1.97
months of the filing date of the above application or date of entry into the nat of an international application or before the mailing date of a first Office action merits, whichever event occurs last. 37 CFR 1.97(b). OR [X] The Information Disclosure Statement submitted herewith is being filed mailing of a first office action after the filing of a Request For Continue Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)). B. [] The Information Disclosure Statement transmitted herewith is being filed after the of the filing date of the above application or the date of entry into the national state forth in § 1.491 of an international application or after the mailing date of the first Action on the merits, whichever event occurred last, but before the mailing date (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first. [] Applicant hereby certifies that each item of information contained in this Informat Disclosure Statement was cited in a communication from a foreign patent office counterpart foreign application not more than three months prior to the filing of the statement. [] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission for the statement.	ĺĴ	Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d)) A copy of the International Search Report which issued on International Application No is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have
The Information Disclosure Statement submitted herewith is being filed mailing of a first office action after the filing of a Request For Continue Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)). B. [] The Information Disclosure Statement transmitted herewith is being filed after the of the filing date of the above application or the date of entry into the national state forth in § 1.491 of an international application or after the mailing date of the first Action on the merits, whichever event occurred last, but before the mailing date (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first. [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office counterpart foreign application not more than three months prior to the filing of the statement. [] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submissions.		
of the filing date of the above application or the date of entry into the national state forth in § 1.491 of an international application or after the mailing date of the first Action on the merits, whichever event occurred last, but before the mailing date (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first. [] Applicant hereby certifies that each item of information contained in this Informat Disclosure Statement was cited in a communication from a foreign patent office counterpart foreign application not more than three months prior to the filing of the statement. [] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submissions.		The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued
Disclosure Statement was cited in a communication from a foreign patent office counterpart foreign application not more than three months prior to the filing of the statement. [] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submissions.	В. []	(2) a notice of allowance under § 1.311,
	[]	Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

Э.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.
	In acco	rdance with the requirements of 37 CFR 1.97(d):
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
	[]	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
	[]	The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
[X] []		charge any required fees to Deposit Account No.07-1392. cate copy of this paper is attached.

Respectfully Submitted,

/Dwight S. Walker/ Dwight S. Walker Agent of Record Registration No. 63,170

Date: May 11, 2010
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398

Telephone: (919) 483-9995 Facsimile: (919) 483-7988